How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)

Details

Database :

OAIster

Journal :

Arendrup , MC , Friberg , N , Mares , M , Kahlmeter , G , Meletiadis , J , Guinea , J , Andersen , CT , Arikan-Akdagli , S , Barchiesi , F , Chryssanthou , E , Hamal , P , Järv , H , Klimko , N , Kurzai , O , Lagrou , K , Lass-Flörl , C , Matos , T , Muehlethaler , K , Rogers , TR , Velegraki , A & Arikan , S 2020 , ' How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST) ' , Clinical Microbiology and Infection , vol. 26 , no. 11 , pp. 1464-1472 .

Notes :

application/pdf, English

Publication Type :

Electronic Resource

Accession number :

edsoai.on1313630463

Document Type :

Electronic Resource